Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Endoscope-Assisted Microneurosurgery for Neurovascular Compression Syndromes: Basic Principles, Methodology, and Technical Notes.

Luzzi S, Del Maestro M, Trovarelli D, De Paulis D, Dechordi SR, Di Vitantonio H, Di Norcia V, Millimaggi DF, Ricci A, Galzio RJ.

Asian J Neurosurg. 2019 Jan-Mar;14(1):193-200. doi: 10.4103/ajns.AJNS_279_17.

2.
3.

Dural repair using autologous fat: Our experience and review of the literature.

Di Vitantonio H, De Paulis D, Del Maestro M, Ricci A, Dechordi SR, Marzi S, Millimaggi DF, Galzio RJ.

Surg Neurol Int. 2016 Jul 7;7(Suppl 16):S463-8. doi: 10.4103/2152-7806.185777. eCollection 2016.

4.

Cavernous hemangioma of the frontal bone: a case report.

Murrone D, De Paulis D, Millimaggi DF, Del Maestro M, Galzio RJ.

J Med Case Rep. 2014 Apr 9;8:121. doi: 10.1186/1752-1947-8-121.

5.

The effects of platelet gel-released supernatant on human fibroblasts.

Giusti I, Rughetti A, D'Ascenzo S, Di Stefano G, Nanni MR, Millimaggi D, Dell'orso L, Dolo V.

Wound Repair Regen. 2013 Mar-Apr;21(2):300-8. doi: 10.1111/wrr.12025. Epub 2013 Feb 25.

PMID:
23438188
6.

Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.

Angelucci A, Mari M, Millimaggi D, Giusti I, Carta G, Bologna M, Dolo V.

Gynecol Oncol. 2010 Dec;119(3):557-63. doi: 10.1016/j.ygyno.2010.07.036. Epub 2010 Sep 9.

PMID:
20825984
7.

Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.

Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna M, Teti A, Angelucci A, Dolo V.

Cancer Res. 2010 Aug 1;70(15):6150-60. doi: 10.1158/0008-5472.CAN-09-2758. Epub 2010 Jul 14.

8.

Isolation and characterization of circulating tissue transglutaminase-specific T cells in coeliac disease.

Ciccocioppo R, Finamore A, Mengheri E, Millimaggi D, Esslinger B, Dieterich W, Papola F, Colangeli S, Tombolino V, Schuppan D, Corazza GR.

Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):179-91.

PMID:
20377989
9.

Vasculogenic mimicry of human ovarian cancer cells: role of CD147.

Millimaggi D, Mari M, D' Ascenzo S, Giusti I, Pavan A, Dolo V.

Int J Oncol. 2009 Dec;35(6):1423-8.

PMID:
19885565
10.

Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels.

Gravina GL, Festuccia C, Millimaggi D, Tombolini V, Dolo V, Vicentini C, Bologna M.

Urology. 2009 Aug;74(2):452-7. doi: 10.1016/j.urology.2009.01.018. Epub 2009 Mar 13.

PMID:
19285710
11.

Identification of an optimal concentration of platelet gel for promoting angiogenesis in human endothelial cells.

Giusti I, Rughetti A, D'Ascenzo S, Millimaggi D, Pavan A, Dell'Orso L, Dolo V.

Transfusion. 2009 Apr;49(4):771-8. doi: 10.1111/j.1537-2995.2008.02033.x. Epub 2008 Dec 23.

PMID:
19170984
12.

Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.

Festuccia C, Gravina GL, D'Alessandro AM, Muzi P, Millimaggi D, Dolo V, Ricevuto E, Vicentini C, Bologna M.

Endocr Relat Cancer. 2009 Jun;16(2):401-13. doi: 10.1677/ERC-08-0130. Epub 2009 Jan 19.

PMID:
19153211
13.

Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment.

Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Ficorella C, Ricevuto E, Bologna M.

Prostate. 2009 Mar 1;69(4):337-45. doi: 10.1002/pros.20884.

PMID:
19016477
14.

Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.

Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M.

Int J Oncol. 2008 Aug;33(2):381-8.

PMID:
18636160
15.

Effects of gliadin stimulation on bone marrow-derived dendritic cells from HLA-DQ8 transgenic MICE.

Ciccocioppo R, Rossi M, Pesce I, Ricci G, Millimaggi D, Maurano F, Corazza GR.

Dig Liver Dis. 2008 Dec;40(12):927-35. doi: 10.1016/j.dld.2008.05.005. Epub 2008 Jun 24.

PMID:
18567549
16.

Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles.

Giusti I, D'Ascenzo S, Millimaggi D, Taraboletti G, Carta G, Franceschini N, Pavan A, Dolo V.

Neoplasia. 2008 May;10(5):481-8.

17.

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.

Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Bologna M.

Prostate. 2008 Jun 15;68(9):965-74. doi: 10.1002/pros.20757.

PMID:
18361408
18.

Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.

Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.

Prostate. 2008 May 15;68(7):793-801. doi: 10.1002/pros.20748.

PMID:
18324645
19.

Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma.

Angelucci A, Muzi P, Cristiano L, Millimaggi D, Cimini A, Dolo V, Miano R, Vicentini C, Cerù MP, Bologna M.

Prostate. 2008 May 1;68(6):588-98. doi: 10.1002/pros.20708.

PMID:
18288684
20.

suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion.

Piccolella M, Festuccia C, Millimaggi D, Locatelli A, Bologna M, Motta M, Dondi D.

Int J Oncol. 2008 Jan;32(1):185-91.

21.

Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.

Festuccia C, Gravina GL, Millimaggi D, Muzi P, Speca S, Ricevuto E, Vicentini C, Bologna M.

Oncol Rep. 2007 Aug;18(2):503-11.

PMID:
17611677
22.

Reduced number and function of peripheral dendritic cells in coeliac disease.

Ciccocioppo R, Ricci G, Rovati B, Pesce I, Mazzocchi S, Piancatelli D, Cagnoni A, Millimaggi D, Danova M, Corazza GR.

Clin Exp Immunol. 2007 Sep;149(3):487-96. Epub 2007 Jun 20.

23.

Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells.

Millimaggi D, Mari M, D'Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, Pavan A, Dolo V.

Neoplasia. 2007 Apr;9(4):349-57.

24.

Detrimental effects of anabolic steroids on human endothelial cells.

D'Ascenzo S, Millimaggi D, Di Massimo C, Saccani-Jotti G, Botrè F, Carta G, Tozzi-Ciancarelli MG, Pavan A, Dolo V.

Toxicol Lett. 2007 Mar 8;169(2):129-36. Epub 2007 Jan 3.

PMID:
17267145
25.

Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.

Festuccia C, Muzi P, Gravina GL, Millimaggi D, Speca S, Dolo V, Ricevuto E, Vicentini C, Bologna M.

Int J Oncol. 2007 Jan;30(1):193-200.

PMID:
17143529
26.

Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways.

Angelucci A, Valentini A, Millimaggi D, Gravina GL, Miano R, Dolo V, Vicentini C, Bologna M, Federici G, Bernardini S.

Anticancer Drugs. 2006 Nov;17(10):1141-50.

PMID:
17075313
27.

Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH.

Taraboletti G, D'Ascenzo S, Giusti I, Marchetti D, Borsotti P, Millimaggi D, Giavazzi R, Pavan A, Dolo V.

Neoplasia. 2006 Feb;8(2):96-103.

28.

Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.

Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, Muzi P, Teti A, Vicentini C, Bologna M.

Endocr Relat Cancer. 2006 Mar;13(1):197-210.

PMID:
16601288
29.

Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells.

Millimaggi D, Festuccia C, Angelucci A, D'Ascenzo S, Rucci N, Flati S, Bologna M, Teti A, Pavan A, Dolo V.

Int J Oncol. 2006 Apr;28(4):909-14.

PMID:
16525640
30.

Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.

Prinetti A, Millimaggi D, D'Ascenzo S, Clarkson M, Bettiga A, Chigorno V, Sonnino S, Pavan A, Dolo V.

Biochem J. 2006 Apr 15;395(2):311-8.

31.

Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.

Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.

Endocr Relat Cancer. 2005 Dec;12(4):983-98.

PMID:
16322337
32.

Alterations of choline phospholipid metabolism in ovarian tumor progression.

Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F.

Cancer Res. 2005 Oct 15;65(20):9369-76.

33.

Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease.

Di Sabatino A, Ciccocioppo R, Cupelli F, Cinque B, Millimaggi D, Clarkson MM, Paulli M, Cifone MG, Corazza GR.

Gut. 2006 Apr;55(4):469-77. Epub 2005 Aug 16.

34.

Shedding of membrane vesicles by tumor and endothelial cells.

Dolo V, D'Ascenzo S, Giusti I, Millimaggi D, Taraboletti G, Pavan A.

Ital J Anat Embryol. 2005;110(2 Suppl 1):127-33.

PMID:
16101030
35.

A novel protein kinase C alpha-dependent signal to ERK1/2 activated by alphaVbeta3 integrin in osteoclasts and in Chinese hamster ovary (CHO) cells.

Rucci N, DiGiacinto C, Orrù L, Millimaggi D, Baron R, Teti A.

J Cell Sci. 2005 Aug 1;118(Pt 15):3263-75. Epub 2005 Jul 12.

36.

Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.

Festuccia C, Angelucci A, Gravina GL, Biordi L, Millimaggi D, Muzi P, Vicentini C, Bologna M.

Thromb Haemost. 2005 May;93(5):964-75.

PMID:
15886816
38.

Intrafollicular expression of matrix metalloproteinases and their inhibitors in normally ovulating women compared with patients undergoing in vitro fertilization treatment.

D'Ascenzo S, Giusti I, Millimaggi D, Marci R, Tatone C, Cardigno Colonna R, Moscarini M, Pavan A, Dolo V, Caserta D.

Eur J Endocrinol. 2004 Jul;151(1):87-91.

PMID:
15248826
39.

Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.

Violini S, D'Ascenzo S, Bagnoli M, Millimaggi D, Miotti S, Canevari S, Pavan A, Dolo V.

J Exp Clin Cancer Res. 2004 Mar;23(1):83-91.

PMID:
15149155
40.

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.

Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, Cifone MG, Corazza GR.

Gut. 2004 Jan;53(1):70-7.

41.

Apoptosis and peripheral blood lymphocyte depletion in coeliac disease.

Di Sabatino A, D'Alò S, Millimaggi D, Ciccocioppo R, Parroni R, Sciarra G, Cifone MG, Corazza GR.

Immunology. 2001 Aug;103(4):435-40.

42.
43.

Culture conditions modulate cell phenotype and cause selection of subpopulations in PC3 prostate cancer cell line.

Festuccia C, Gravina GL, Angelucci A, Millimaggi D, Bologna M.

Anticancer Res. 2000 Nov-Dec;20(6B):4367-71.

PMID:
11205273
44.

Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-gamma production.

Cifone MG, D'Alò S, Parroni R, Millimaggi D, Biordi L, Martinotti S, Santoni A.

Blood. 1999 Jun 1;93(11):3876-84.

45.

Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components.

Festuccia C, Bologna M, Gravina GL, Guerra F, Angelucci A, Villanova I, Millimaggi D, Teti A.

Int J Cancer. 1999 May 5;81(3):395-403.

46.

Supplemental Content

Loading ...
Support Center